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For some neurological disorders, disease is primarily
RNA mediated due to expression of non-coding mi-
crosatellite expansion RNAs (RNAexp). Toxicity is
thought to result from enhanced binding of proteins
to these expansions and depletion from their normal
cellular targets. However, experimental evidence for
this sequestration model is lacking. Here, we use
HITS-CLIP and pre-mRNA processing analysis of
human control versus myotonic dystrophy (DM)
brains to provide compelling evidence for this RNA
toxicity model. MBNL2 binds directly to DM repeat
expansions in the brain, resulting in depletion from
its normal RNA targets with downstream effects
on alternative splicing and polyadenylation. Similar
RNA processing defects were detected inMbnl com-
pound-knockout mice, highlighted by dysregulation
of Mapt splicing and fetal tau isoform expression in
adults. These results demonstrate that MBNL pro-
teins are directly sequestered by RNAexp in the DM
brain and introduce a powerful experimental tool to
evaluate RNA-mediated toxicity in other expansion
diseases.
INTRODUCTION
Microsatellites, or simple sequence repeats of %10 bp, com-
prise 3% of the human genome but are generally regarded
as non-functional and neutrally evolving (Gemayel et al., 2010;CellGoodwin and Swanson, 2014). However, these repeats are
highly polymorphic in size, and expansions cause >40 hereditary
neurological and neuromuscular disorders (Nelson et al., 2013).
Current pathogenesis models propose that these diseases are
most commonly caused by either mutant expansion proteins
or RNAs, depending on the location of the mutation within
each affected gene. For example, coding region expansions
generate mutant proteins containing elongated homopolymeric
tracts, while expansions in non-coding regions result in the syn-
thesis of toxic RNAs that either sequester or trigger the activation
of RNA processing factors (Echeverria and Cooper, 2012). How-
ever, repeat-associated non-ATG (RAN) translation also occurs
in several expansion diseases, including spinocerebellar ataxia
type 8 (SCA8) and C9orf72 amyotrophic lateral sclerosis and
frontotemporal dementia (C9 ALS/FTD), so toxic proteins may
also be produced from classically defined non-coding regions
(Kwon et al., 2014; Mizielinska et al., 2014; Mori et al., 2013b;
Wen et al., 2014; Zu et al., 2011, 2013).
Studies on the molecular etiology of myotonic dystrophy (DM)
have served as a model to investigate RNA-mediated toxicity
mechanisms. Indeed, the sequestration and activation of RNA
processing factors as well as RAN translation have been docu-
mented in this disease (Cleary and Ranum, 2014; Echeverria
and Cooper, 2012; Mohan et al., 2014). DM types 1 and 2
(DM1 and DM2) are progressive and multi-systemic neuromus-
cular disorders with cardinal manifestations including myotonia,
muscle wasting, cardiomyopathy, excessive daytime sleepi-
ness, cerebral atrophy, white matter lesions, cognitive impair-
ments, and neurofibrillary tangles (NFTs). DM1 is caused by
CTGexp mutations in the 30 UTR of the DMPK gene, while DM2
is associated with a CCTGexp in intron 1 of CNBP/ZNF9. Tran-
scription of these repeats results in the synthesis of C(C)UGexpReports 12, 1159–1168, August 18, 2015 ª2015 The Authors 1159
Figure 1. HITS-CLIP Identifies MBNL2-RNAexp Interactions in DM
Brain
(A) Strategy for identifying RBP-RNAexp-binding interactions using HITS-CLIP.
For DM1, a CTG repeat (red box) in the DMPK 30 UTR (coding exons, thick
black boxes; UTRs, thin black boxes; introns, thin lines) expands in disease
(CUGexp, red triangle). Upon transcription, the mRNA (gray) forms a stem loop
that sequesters MBNL2 (blue ovals). HITS-CLIP of MBNL proteins using DM1
(right), but not control (left), tissue generates a large increase in reads clustered
over the repeat region (bottom right).
(B) MBNL2 binding profile reveals enriched binding to the DMPK CTGexp in
DM1 brain. UCSC browser view showing wiggle plots of MBNL2 HITS-CLIP
binding in the DMPK reference gene for control (orange), DM1 (green), and
DM2 (blue) human hippocampus. Zoomed-in view of the terminal exon (bot-
1160 Cell Reports 12, 1159–1168, August 18, 2015 ª2015 The AuthoRNAs that alter the RNA processing activities of several RNA-
binding factors, including CELF and MBNL proteins (Echeverria
and Cooper, 2012). For MBNL, C(C)UGexp RNAs co-localize with
MBNL1-3 in nuclear RNA foci, and this protein redistribution is
thought to inhibit the normal functions of this protein family in
alternative pre-mRNA splicing (AS), alternative polyadenylation
(APA), pre-microRNA processing, and RNA localization (Batra
et al., 2014; Fardaei et al., 2002; Ho et al., 2004; Jiang et al.,
2004; Miller et al., 2000; Rau et al., 2011; Wang et al., 2012).
The MBNL loss-of-function model is also supported by studies
onMbnl single- and compound-knockout mice, which recapitu-
late many DM postnatal phenotypes (Charizanis et al., 2012; Ka-
nadia et al., 2003; Lee et al., 2013a; Poulos et al., 2013). Never-
theless, the interaction of MBNL proteins with C(C)UGexp RNAs
may be indirect andmediated by other factors in affected human
tissues. Indeed, additional proteins bind to C(C)UGexp RNAs
(Kim et al., 2005; Pettersson et al., 2014; Ravel-Chapuis et al.,
2012) or co-localize with nuclear foci (Laurent et al., 2012).
Here, we use high-throughput sequencing-crosslinking immu-
noprecipitation (HITS-CLIP) combined with pre-mRNA process-
ing analysis to demonstrate that MBNL proteins regulate AS and
APA in the human brain and these functions are dysregulated in
DM due to direct MBNL binding to C(C)UGexp RNAs and deple-
tion of these proteins from their normal RNA targets. Based on
these results, we propose this in situ strategy to validate candi-
date sequestered factors in other microsatellite expansion dis-
eases, including C9 ALS/FTD.
RESULTS
Direct Titration ofMBNL2byC(C)UGexp RNAs inDM1and
DM2 Brains
Given that MBNL2 is the major MBNL family member respon-
sible for DM-associated splicing abnormalities in the brain (Char-
izanis et al., 2012), we reasoned that if MBNL2 binds directly to,
and is sequestered by, C(C)UGexp RNA in vivo, then MBNL2
HITS-CLIP performed on DM1 brain should produce CUG-rich
reads that cluster over the CTG repeat region in the 30 UTR of
the DMPK reference gene (Figure 1A). To test this possibility,
MBNL2HITS-CLIPwas performed for DM1 and neurological dis-
ease controls using autopsy tissue from two brain regions
affected in DM: the hippocampus and frontal cortex (Table S1).
Sequencing reads were aligned back to the human reference
genome, and wiggle plots were used to visualize MBNL2 binding
distribution. As predicted by the direct binding and sequestration
model, a large peak of MBNL2 CLIP tags was observed over the
DMPK 30 UTR CTG repeat region in DM1 hippocampus
compared to the few CLIP tags that mapped to this region for
non-DM disease controls and DM2 (Figure 1B). The averagetom right) showing a clustered read peak over the CTG repeat region for DM1
only. Quantification (bottom left) of MBNL2 CLIP peak read depth (RPKM) over
the DMPK CTG repeat region shows a significant enrichment (36-fold) over
controls (n = 3 per group, data are reported ±SEM, *p < 0.05).
(C) MBNL2 HITS-CLIP binding profile for CNBP. Intron 1 (bottom right) con-
taining the CCTG repeat region (red box) is shown. Quantification (bottom left)
of average peak read depth over CCTG repeats showing a 79-fold enrichment
in DM2 over controls (n = 3 per group; data are reported ±SEM; ***p < 0.001).
rs
Figure 2. Depletion of MBNL2 Binding for
Misregulated Exons in DM1
(A) Venn diagram of overlapping MBNL2 target
genes in human hippocampus and frontal cortex
and mouse hippocampus.
(B) Pie chart of MBNL2 binding site distribution in
human hippocampus.
(C) Venn diagram of common genes in DM1 and
DM2 with MBNL2 depletion events identified by
dCLIP analysis.
(D) UCSC browser view of MBNL2 dCLIP near
CSNK1D exon 9 (left) (alternative exon, red box;
flanking exons, thick black boxes; introns, gray
lines) and APP exon 7 (right) showing loss of
binding in DM1 (green) compared to controls (or-
ange) (n = 3 each). RT-PCR splicing analyses are
also shown for CSNK1D and APP in control versus
DM1 brain with corresponding percent spliced in
(J) values (n = 3 per group; data are reported
±SEM; ***p < 0.001, **p < 0.01).read depth over the repeat region was significantly enriched in
DM1 (>36-fold over controls). Similar binding to CUG repeats
was observed in the frontal cortex (Figure S1A), demonstrating
that MBNL2 was sequestered in both regions of the brain.
A parallel analysis was performed to assess MBNL2 binding
to the CCUG repeat RNA in DM2 (Figure 1C). In contrast to
DM1, a peak of MBNL2 binding occurred in the region corre-
sponding to CNBP intron 1 in the CCUG repeat region in DM2,
but not in control or DM1. Quantification of average read depth
showed a 79-fold enrichment (1/10 SD added over zero control
reads) of MBNL2 binding to the CCUG repeat region in DM2
versus controls. Enrichment of CTG and CCTG repeat reads in
the raw datasets was also assessed to address signal loss due
to microsatellite misalignment. The excess of pre-alignment
repeat reads confirmed the abundance of MBNL binding sites
in DM1 and DM2 (Table S1; Figure S1B). This strong enhance-
ment of MBNL2 binding to the C(C)UGexp regions in DM1 and
DM2 brains not only supported the protein sequestration model
but also demonstrated the potential utility of HITS-CLIP for au-
thenticating factors implicated in RNA toxicity in other microsat-
ellite expansion disorders.
MBNL2 Sequestration and RNA Splicing Defects in the
DM CNS
Given that HITS-CLIP demonstrated enhanced MBNL2 binding
to C(C)UG repeat regions in DM1 and DM2 brains, we next ad-
dressed the hypothesis that this toxic RNA binding results in
depletion of MBNL2 binding to its normal pre-mRNA targets.
Analysis of MBNL2 binding to normal RNA targets identified byCell Reports 12, 1159–1168,HITS-CLIP of control brain revealed con-
siderable overlap of target genes be-
tween the hippocampus and frontal cor-
tex (Figure 2A). In addition, a significant
portion of MBNL2 gene targets in the
human hippocampus overlapped with
hippocampal targets of murine Mbnl2
(Charizanis et al., 2012). Comparison of
MBNL2 HITS-CLIP tags from humanand mouse hippocampus indicated that tag distribution was
similar, with 67% of human MBNL2 tags mapping to the 30
UTR (Figure 2B) versus 51% in mouse (Charizanis et al., 2012),
and the preferred binding motif (YGCY, Y = T/U or C) was
conserved between species (Figure S2A). Gene ontology (GO)
analysis also indicated that MBNL2 targets were involved in
similar pathways in human (Figure S2B) compared to mouse
(Charizanis et al., 2012).
To determine whether MBNL2 is titrated away from its normal
pre-mRNA targets in DM, we performed a comparative analysis
of MBNL binding in control and DM1 patient brains using differ-
ential CLIP (dCLIP) (Wang et al., 2014). The dCLIP computational
pipeline normalizes HITS-CLIP read data across different data-
sets for comparison and identifies statistically significant
changes in the amount of RBP binding between two different
conditions using a hidden Markov model (HMM). The dCLIP
comparative analysis of human MBNL2 binding interaction in
control versus DM brain defined 2,781 transcripts in DM1 and
2,062 transcripts in DM2 that showed reduced binding of
MBNL2, with considerable overlap (1,765) between the two dis-
ease types (Figures 2C; Table S2). MBNL2 depletion occurred
predominantly in 30 UTRs followed by introns (Figures S2C and
S2D), reflecting the typical binding distribution of MBNL2.
To determinewhetherMBNL2 depletion near target alternative
exons resulted in misregulated splicing in the DM brain, MBNL2
dCLIP profiles were analyzed for alternative cassette exons mis-
spliced in DM1 (Figure S2E) (Charizanis et al., 2012; Jiang et al.,
2004). Splicing patterns were analyzed by RT-PCR splicing as-
says using primers that annealed to exons flanking misregulatedAugust 18, 2015 ª2015 The Authors 1161
Figure 3. Reversal to Fetal CNS Splicing
Due to Combined Loss of MBNL1 and
MBNL2
(A) Kaplan-Meier analysis of Mbnl1DE3/DE3,
Mbnl2c/c; Nestin-Cre+/ (Nestin-Cre DKO) mice,
wild-type (WT; Mbnl1+/+, Mbnl2+/+), and Cre con-
trols (Mbnl1+/+,Mbnl2+/+;Nestin-Cre+/;Mbnl1+/+,
Mbnl2c/c; Nestin-Cre+/; Mbnl1DE3/DE3, Mbnl2c/c;
Nestin-Cre/) (n = 21 per group).
(B) Accelerating rotarod performance of Nestin-
Cre DKO mice and controls (5 weeks of age) over
the 4-day training course (n R 8 per group; data
are reported ±SEM; ***p < 0.001).
C) RT-PCR analysis of splicing patterns in WT,
Mbnl1DE3/DE3,Mbnl2 DE2/DE2, and Nestin-Cre DKO
brain showing several targets (Add1, Kcnma1,
Clasp2) with increased missplicing after com-
pound loss of Mbnl function.
(D) Reversal to fetal splicing patterns inNestin-Cre
DKO brain. The splicing patterns of four Camk2d
isoforms in WT to Mbnl1DE3/DE3, Mbnl2 DE2/DE2,
and Nestin-Cre DKO brain are compared to the
splicing patterns of WT postnatal day 6 (P6) and
P42 mice.cassette exons, and the percentage of exon inclusion was quan-
tified as percent spliced in (J). For example, enhanced skipping
of CSNK1D exon 9 and APP exon 7 occurs in the DM1 brain, and
reduced binding of MBNL2 near these alternative exons was
observed by dCLIP (Figure 2D). These results indicate that
expression of mutant DMPK and CNBP alleles leads to MBNL
sequestration on C(C)UGexp RNAs, resulting in dysregulation of
RNA splicing in the brain.
Although dCLIP analysis supported the MBNL sequestration
model, an alternative strategy was performed to confirm that
depletion of MBNL activity in the brain recapitulated DM-associ-
ated RNAmissplicing. Sincewe have recently demonstrated that
MBNL1 andMBNL2 compensate for each other to regulate alter-
native splicing (Lee et al., 2013a), depletion of MBNL activity was
achieved in amouseMbnl compound-knockout model, because
prior work has shown that loss of bothMbnl1 andMbnl2 expres-
sion in mouse skeletal muscle is required to recapitulate the RNA
misprocessing events characteristic of DM (Batra et al., 2014;
Lee et al., 2013a).
Mbnl1; Mbnl2 Knockout Mice Model DM1-Associated
Missplicing
Mbnl1; Mbnl2 conditional double-knockout (Mbnl1/;Mbnl2c/c;
Nestin-Cre+/ or Nestin-Cre DKO) mice were generated that
were Mbnl1 constitutive nulls with Mbnl2 expression selectively
ablated in the nervous system. Nestin-Cre DKOs were small,
similar to Mbnl2/ single-knockout mice (Figure S3A). In
contrast to Mbnl2/ mice (Charizanis et al., 2012), the DKOs
only survived until 23 weeks of age (Figure 3A) and showed
early-onset severe motor (Figure 3B) and grip (Figure S3B) defi-
cits. Alternative splicing patterns were compared for wild-type
(WT) (Mbnl1+/+; Mbnl2+/+; Nestin-Cre+/), Mbnl1 KO (Mbnl1/;
Mbnl2c/c; Nestin-Cre/), Mbnl2 KO (Mbnl1+/+; Mbnl2c/c; Nes-
tin-Cre+/), and Nestin-Cre DKO brains (Figures 3C, 3D, and
S3C). As anticipated, compound loss of MBNL1 and MBNL2 in1162 Cell Reports 12, 1159–1168, August 18, 2015 ª2015 The Authothe nervous system significantly enhanced missplicing of alter-
native exons, such as Add1 E15, Kcnma1 E25a, and Clasp2
E16 (Figure 3C), previously identified in Mbnl2 KO and DM1
(Charizanis et al., 2012). Importantly, the Nestin-Cre DKO adult
and WT fetal/neonatal splicing patterns were similar in these
targets and in Camk2d (Suenaga et al., 2012), indicating that
compound loss of MBNL1 and MBNL2 is required for loss of
adult exon splicing in the mammalian brain (Figure 3D). More-
over, comparison of the Nestin-Cre DKO with DM1 and DM2
brains showed the same alternative splicing trend. For example,
splicing of mouse Cacna1d exon 12a in the brain was almost
completely blocked in Nestin-Cre DKOs, while splicing of the
orthologous human exon was reduced in DM1 and DM2 (Fig-
ure 4A). A striking concordance was also observed for enhanced
inclusion of Grin1/GRIN1 exon 5 between Nestin-Cre DKOs and
DM1 (Figure 4B). We conclude that Mbnl depletion in the mouse
brain recapitulates the aberrant CNS splicing patterns character-
istic of DM1 and DM2.
To extend these results and examine the global relationship
between human and mouse MBNL protein binding and alterna-
tive splicing regulation, RNA sequencing (RNA-seq) data were
generated from human DM1 and control frontal cortex (Table
S3). We identified 596 alternative exons with lower inclusion,
and 335 exons with higher inclusion, in DM1 corresponding to
cassette exons activated and repressed by MBNL proteins,
respectively. Next, we generated normalized complexity maps
to correlate these changes on a global level with MBNL binding,
using both HITS-CLIP data (Table S1) and predicted functional
YGCY motifs (Zhang et al., 2013) (Figure 4C). Compared to
mouse Mbnl2/ KO brain (Charizanis et al., 2012), the human
exon inclusion pattern indicates that MBNL binding proximal
to both the 50 splice site (ss) and 30 ss promotes alternative
cassette splicing. The exon exclusion pattern is similar between
mouse and human, although a larger peak was observed near
the downstream flanking exon 30 ss. Surprisingly, this RNA-seqrs
Figure 4. DM-Relevant Missplicing in Nes-
tin-Cre DKO Brain
(A) RT-PCR splicing analysis of Cacna1d in WT,
Mbnl1DE3/DE3,Mbnl2 DE2/DE2, and Nestin-Cre DKO
brain. Splicing of CACNA1D in human control,
DM2, and DM1 brain shown for comparison (n = 3
per group; data are reported ±SEM; ***p < 0.001,
**p < 0.01).
(B) Same as (A), but splicing analysis of mouse
Grin1 compared to humanGRIN1 (n = 3 per group;
data are reported ±SEM; *p < 0.05).
(C) RNA splicing maps using human MBNL2
CLIP tags near exons misspliced in the DM1
frontal cortex (included exons, red; skipped
exons, blue; coverage R 20, jdIj R 0.1, FDR %
0.05). Also included is MBNL-binding motif data,
or YGCY motifs in the human genome near the
misspliced exons, using a previously described
computational procedure (included exons, light
red; skipped exons, light blue) (Zhang et al.,
2013).analysis revealed that human microtubule-associated protein
tau (MAPT) exons 2, 3, and 10 were some of the most misspliced
cassette exons in the DM1 frontal cortex (Table S3). Given that a
prominent manifestation of DM1 CNS disease is the progressive
appearance of neurofibrillary tangles (NFTs) composed of intra-
neuronal aggregates of hyper-, and abnormally, phosphorylated
tau protein as well as expression of fetal MAPT isoforms (Ser-
geant et al., 2001), we next investigated the effect of loss of
MBNL activity on MAPT pre-mRNA splicing regulation.
Aberrant Tau Processing in DM1 and Mbnl Compound
Knockouts
In the human adult brain, MAPT encodes six tau isoforms
through the alternative splicing of exons 2, 3, and 10 (exons 3,
4, and 8 in mouse), but in DM, all three of these exons are skip-
ped so that fetal tau is preferentially expressed (Dhaenens et al.,
2008; Jiang et al., 2004). Although MAPT minigene studies have
shown that synergistic interactions betweenMBNL1 andMBNL2
activate the splicing of MAPT exons 2 and 3, it is not clear
whether these MBNL interactions are important in vivo (Carpent-
ier et al., 2014). To address this point, Mapt exon 2 and 3 splicing
in the brain was examined using Mbnl2/ single KO versus
Nestin-Cre DKO and compared to control and DM1 human
MAPT splicing. The results indicated thatMbnl1 andMbnl2 inter-
actions were also essential in vivo, since the DM1 pattern of pre-
dominant skipping of Mapt exons 2 and 3 was only observed in
the DKOmice, similar to the enhanced skipping of these exons in
DM1 compared to control brain (Figures 5A and S3D).
In contrast to MAPT exons 2 and 3, MBNL-mediated regula-
tion ofMAPT exon 10 has not been reported previously (Carpent-
ier et al., 2014). Interestingly, dCLIP and crosslinked induced
mutation site (CIMS) analysis of MBNL2 binding in hippocampus
revealed that this MBNL protein bound primarily to YGCY clus-
ters within intron 10 (Figures 5B and S4). Although the mouse or-Celltholog also recognized YGCY motifs in intron 10, a major Mbnl2
binding peak was also detectable in Mapt intron 9 upstream of
the exon 10 30 ss (Figure 5B). This difference in binding distribu-
tion is intriguing, because in human adult brain, equivalent inclu-
sion and exclusion of MAPT exon 10 occurs in control brain,
although in adult mouse brain, exon 10 inclusion is favored (Fig-
ure 5C). Although knockout of Mbnl2 produced only a modest
shift toward exclusion of this exon, combinatorial loss of Mbnl1
and Mbnl2 in the DKO brain triggered a strong change toward
exclusion (Figures 5C and S3D), suggesting that both MBNL1
and MBNL2 synergize to control MAPT exon 10 splicing.
Given that MAPT missplicing should result in abnormal ex-
pression of tau protein isoforms, MBNL-dependent changes in
tau expression and phosphorylation status were assessed. The
relative amounts of tau protein isoforms and post-translational
modification (PTM) were compared for WT, Mbnl1 knockout,
Mbnl2 knockout, and Nestin-Cre DKO mouse brains using 2D
gel electrophoresis (2D-GE) coupled with immunoblotting (Fig-
ure 5D). The alternative splicing of exons 2, 3, and 10 results in
six tau protein isoforms in the adult brain that differ based on in-
clusion of two 29-amino-acid N-terminal inserts (0N, 1N, or 2N)
encoded by exons 2 and 3 and an additional microtubule-bind-
ing domain encoded by exon 10 that generates the tau 4R iso-
form. As expected, loss ofMbnl1 alone did not significantly alter
Mapt splicing or protein isoform expression. Mbnl1 KO tau
expression patterns resembled WT, including isoforms with 0,
1, and 2 N-terminal inserts and all four microtubule-binding do-
mains (0N4R, 1N4R, and 2N4R). In Mbnl2 KO brain, a shift to-
ward diminished expression of 1N4R and 2N4R isoforms
occurred with more acidic isovariants of the 0N4R isoform.
More strikingly, in the Nestin-Cre DKO brain, the 1N4R and
2N4R isoforms were undetectable, and this change was accom-
panied by the emergence of a 0N3R isoform lacking the fourth
microtubule-binding domain (Figure 5D, fourth panel). SpecificReports 12, 1159–1168, August 18, 2015 ª2015 The Authors 1163
Figure 5. Tau Isoform Misregulation in DM1 and Mbnl DKO Brain
(A) RT-PCR splicing analysis showing shift toward skipping of MAPT exons 2
and 3 in DM1 brain compared to controls and in Nestin-Cre DKO brain relative
to WT.
(B) MBNL2 binding is reduced near MAPT exon 10 in DM1 brain compared to
controls. UCSC browser view of MBNL2 dCLIP binding profiles near MAPT
exon 10 (alternative exon, red box; flanking exons, thick black boxes; introns,
gray lines) in control (orange) and DM1 (green) brain (n = 3). Bottom panel
shows the mouse Mbnl2 HITS-CLIP binding profile near exon 10.
(C) RT-PCR analysis of MAPT/Mapt exon 10 splicing for human control versus
DM1 and mouse wild-type (WT), Mbnl2 KO (Mbnl2/), and Nestin-Cre DKO
(DKO).
(D) Two-dimensional gel electrophoresis (first dimension, 3–11 non-linear pH
gradient strips; second dimension, SDS-PAGE) and immunoblot of tau iso-
forms (2N4R, 1N4R, 0N4R, and 0N3R) in WT,Mbnl1DE3/DE3 (Mbnl1 KO),Mbnl2
DE2/DE2 (Mbnl2 KO), and Nestin-Cre DKO brain. Bottom panel corresponds to
tau staining after treatment with lambda phosphatase. Tau protein was stained
with the a-TauCter antibody. The N-terminal inserts correspond to inclusion/
exclusion of alternative exon 2 and exons 2 + 3. The 3R and 4R isoforms
correspond to isoforms without/with the exon 10 encoding sequence.anti-tau 4R and 3R antibodies confirmed loss of 2N4R and 1N4R
expression and expression of both the 0N4R and 0N3R isoforms
(Figure S5A). Noteworthy, the amount of 0N4R isoform was
strongly reduced in DKOs compared to WT.
To determine whether phosphorylation accounts for the PTMs
responsible for the acidic isoforms, Nestin-Cre DKO brain ho-
mogenate was treated with l-phosphatase, which resulted in
the loss of the more acidic isoforms (Figure 5D). The additional
band at 70 kDa was recognized by a-tauCter and could corre-
spond to hyperphosphorylated tau, but this band was not de-
tected by other anti-tau antibodies (Figure S5B), identifying it
as a non-tau protein. Overall, these results support the hypothe-
sis that loss of MBNL binding to MAPT intron 10 in DM results in
reversion of MAPT pre-mRNA splicing to the fetal pattern.1164 Cell Reports 12, 1159–1168, August 18, 2015 ª2015 The AuthoAlternative Poly(A) Site Selection following MBNL
Sequestration in the Brain
Although the alternative splicing function of MBNL proteins has
been well characterized, MBNL activity is also required for skel-
etal muscle APA regulation (Batra et al., 2014). The high propor-
tion of MBNL2 binding sites in target RNA 30 UTRs revealed by
HITS-CLIP (Figure 2B) led us to speculate that C(C)UGexp-
induced MBNL2 sequestration also results in APA dysregulation
in the brain. To test for APA changes in DM1, we employed a
high-throughput poly(A)-sequencing (poly(A)-seq) strategy (Derti
et al., 2012). Poly(A)-seq libraries were prepared from control,
DM1, and DM2 frontal cortex, and sequencing reads were map-
ped to the human reference genome followed by computational
removal of templated A-rich tracts (Table S4) (Batra et al., 2014).
To assess Mbnl-dependent APA changes in the brain, poly(A)-
seq libraries were also prepared for control and Nestin-Cre
DKO frontal cortex. Scatterplots were generated to quantify
poly(A) site (pA site) use, and significant changes in utilization
of alternative pA sites were recorded (FDR % 0.05 and dI R
I0.15I). This analysis identified APA changes for thousands of
genes in both DM1 (n = 6,647 events, 2,826 genes) and DM2
(n = 5,563 events, 2,425 genes) (Figure 6A) as well as Nestin-
Cre DKO frontal cortex (n = 3,195 events, 1,556 genes) (Fig-
ure 6B), with 502 genes misregulated in both species (Figures
S6A and S6B; Table S4). Shifts to more proximal and distal pA
sites were observed in the Nestin-Cre DKO and DM1 (48%
and 58%, respectively) with a slight bias toward more proximal
sites in the DM brain (Figures 6A and 6B). Thus, MBNL activity
promotes both utilization and skipping of alternative pA sites in
the brain. Interestingly, some genes showed abnormal regulation
of both APA and AS in DM1 hippocampus (Figure S6C). Similar
to the reported splicing targets of MBNL2, many of the APA tar-
gets are involved in pathways associatedwith neuronal functions
and the neurotrophin-signaling pathway as determined by GO
analysis (Figure S6D). In addition, pathway analysis identified en-
riched terms associated with ubiquitin-mediated proteolysis and
the mTOR pathway, remarkably similar to enriched terms identi-
fied by poly(A)-seq analysis of DM skeletal muscle (Batra et al.,
2014).
Analysis of poly(A)-seq profiles in individual genes revealed
examples of APA shifts in the DM brain that were reproduced
in Nestin-Cre DKOs. For example, two alternative pA sites exist
in the 30 UTR of the FZR1 gene, and a shift toward distal site uti-
lization occurs in the DM1 frontal cortex (Figure 6C). Similarly,
this APA shift occurs in mouse DKO frontal cortex. In many
cases, APA shifts resulted in the selection of an intronic pA site
(Figure 6D), which in some cases was conserved between hu-
man and mouse (Figure S6E). Taken together, the results from
HITS-CLIP, dCLIP, RNA-seq, and poly(A)-seq support themodel
that sequestration of MBNL proteins by C(C)UGexp RNA and
subsequent loss of binding from endogenous pre-mRNA targets
leads to dysregulated RNA processing in the DM brain.
DISCUSSION
RNA-mediated pathogenesis has emerged as an important dis-
ease mechanism for a number of neurological and neuromus-
cular disorders caused by microsatellite expansions (Mohanrs
Figure 6. Disrupted Polyadenylation in Human DM and MouseMbnl
DKO Brain
(A) Scatterplot representation of poly(A)-seq data showing APA shifts to more
distal (blue)orproximal (red)pAsites relative to thecoding region inDM1 (top)and
DM2 (bottom) versus control brain (FDR < 0.05, jdIj > 0.15). The data represent
distal (n = 2,794), proximal (3,853), total (6,647), and no shift (25,357) in DM1 and
distal (2,273), proximal (3,290), total (5,563), and no shift (27,683) in DM2.
(B) Scatterplot illustrating shifts tomore distal (blue) or proximal (red) pA sites in
Nestin-Cre DKO versus WT brain (FDR < 0.05, jdIj > 0.15). The data represent
distal (1,668), proximal (1,528), total (3,195), and no shift (47,944).
(C) Poly(A)-seq wiggle plots showing shifts to distal poly(A) sites in the FZR1 30
UTR (30 UTR, thin black box; coding region, thick black boxes; intron, gray line)
in DM1 versus control (top) and Nestin-Cre DKO versus WT (middle). RT-PCR
validation (bottom) of FZR1/Fzr1 switches (distal, D; total, T; n = 3 per group,
data are reported ± SEM, *p < 0.05, ***p < 0.001).
Cellet al., 2014; Nelson et al., 2013). This unusual pathogenic pro-
cess has been implicated in diseases in which the expansion
mutation originates in a non-coding gene, such as ATXN8/ATX-
N8OS, or in the non-coding regions (introns, 50 UTR, 30 UTR) of a
protein-encoding gene. Current disease models propose that
these microsatellite expansion RNAs are toxic because they
either directly sequester and/or indirectly activate cellular factors
or generate RAN peptides via an unconventional translational
mechanism (Cleary and Ranum, 2014). Here, we tested whether
HITS-CLIP, splicing, and polyadenylation analyses could be
combined to assess the binding and sequestration of proteins
by microsatellite expansion RNAs, and corresponding depletion
from endogenous RNA targets, isolated from affected human
brains. Our results demonstrate that MBNL proteins are directly
sequestered by mutant DMPK and CNBP RNAs in DM1 and
DM2 brains, respectively, and the resulting depletion of MBNL
activity reverts specific pre-mRNA processing events to a fetal
regulatory pattern.
MBNL2 Entrapment by Toxic RNAs in the DM Brain
MBNL loss of function in DM is a prominent example of factor
sequestration by disease-associated microsatellite expansion
RNAs and the resulting downstream effects on cell function. In
this study, we demonstrate that the major MBNL protein in the
brain, MBNL2, interacts directly with DM1 CUGexp and DM2
CCUGexp RNAs in the brain. As anticipated, CTG and CCTG
sequence reads also mapped to other repeat-containing genes,
including the antisense strands ofAR andMAML3with 22 and 19
CTG repeats, respectively) (Table S2D). Mapping to C(C)TG/
CA(G)G repeats at these other genomic loci is due to misalign-
ment of pure repeat reads, which results in an underestimation
of mutant DMPK and CNBP binding events. Improved seq-
uencing and mapping technologies may overcome this chal-
lenge in future HITS-CLIP studies and will likely reveal more
robust MBNL sequestration by DM1 and DM2 expansion muta-
tion RNAs.
We also observed loss of MBNL2 binding proximal to mis-
spliced exons in both DM1 and DM2, supporting the model
that MBNL2 sequestration compromises its function as a
splicing regulator in DM. Similarly, coupling poly(A)-seq analysis
and dCLIP revealed loss of MBNL2 binding in 30 UTRs and APA
changes in the same targets, supporting the hypothesis that
MBNL2 controls normal APA regulatory function and this func-
tion is altered in the DM CNS. These pre-mRNA processing
changes are strikingly similar to those observed in Nestin-Cre
DKO mice, indicating that disease-associated changes in AS
and APA are due to direct depletion of MBNL proteins from their
normal target RNAs.
Recently, anotherMBNL activity has been proposed. RNA and
RAN toxicity may be coupled in some microsatellite expansion
diseases, since MBNL1 promotes nuclear accumulation of
mutant CUGexp and CAGexp RNAs that, in turn, represses syn-
thesis of the corresponding RAN proteins in the cytoplasm(D) Wiggle plots (left) of poly(A)-seq data for Sptb and Rgs9 comparing APA
patterns in WT versus Nestin-Cre DKO brain. RT-PCR validation (middle) of
APA changeswith quantification (right) of distal (D) versus total (T) pA utilization
(n = 3 per group, data are reported ± SEM, **p < 0.01, ***p < 0.001).
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(Kino et al., 2015). Alternatively, MBNL proteinsmay also bind re-
peats in the cytoplasm and directly block recruitment of the
translational machinery. Of course, these potential mechanisms
are not mutually exclusive. Although it remains important to dis-
criminate the toxic effects of protein sequestration and RAN
translation (Mizielinska et al., 2014), both mechanisms might
be susceptible to therapeutic strategies designed to upregulate
MBNL protein levels (Kanadia et al., 2006).
Regulation of MAPT Splicing by MBNL Proteins
Abnormal expression of tau fetal isoforms is a characteristic
feature of the adult DM1 brain, and compound loss of MBNL1
and MBNL2 recapitulates this reversion to fetal Mapt RNA and
protein expression in the Nestin-Cre DKO model. Moreover,
tau isoform expression is profoundly modified in the Nestin-
Cre DKO brain but is not associated with a major change in tau
phosphorylation status. However, the changes in tau PTMs
occur with aging in the human disease, whereas the DKO mice
are young adults. Therefore, we cannot exclude the possibility
that tau PTMs could occur in older animals if they survived
beyond 23 weeks of age. Noteworthy, tau isovariants were
more acidic in the Nestin-Cre DKO mice than in WT mice, sug-
gesting that tau PTMs may also be deregulated in this disease
model. Interestingly, MBNL1 alone does not significantly alter
Mapt splicing and MBNL2 primarily regulates exon 2 and exon
2/3 splicing (Carpentier et al., 2014), while loss of both MBNL
proteins caused skipping of exons 2, 3, and 10. Although the
tau 3R isoform is expressed in the mouse fetal, but not adult,
brain (Liu and Go¨tz, 2013), both the 3R and 4R tau isoforms
are found in the human brain, where both MBNL1 and MBNL2
are expressed. Therefore, the regulation of MBNL1 or MBNL2
expression, or their splicing activity, may control tau isoform
expression. For instance, in DM1, the loss of exons 2 and 10 in-
clusion indicates dual loss of MBNL1 andMBNL2 function, since
tau protein isoforms expressed in DM1 brains consist mainly
of tau 0N3R and 0N4R, which is reproduced in Nestin-Cre
DKO mice. Because this deregulation may also depend on the
relative level of MBNL expression, polymorphisms associated
with MBNL expression could also contribute to disease severity
(Huin et al., 2013).
A remaining question is how MBNL proteins control MAPT
exon 10 splicing. Interestingly, HITS-CLIP identified sites for
MBNL2 binding that are located within intron 10 but downstream
of the exon 10-intron 10 junction region previously implicated
in themisregulation ofMAPT exon 10 in frontotemporal dementia
with parkinsonism linked to chromosome 17 (FTDP-17) (Niblock
and Gallo, 2012). Given that prior studies have proposed that
additional splicing factors, including RBM4, CELF3, and
CELF4, also bind to intron 10 to promote exon 10 splicing, it
will be important to map these binding sites in the human brain
and compare their binding patterns to MBNL2.
In Situ Validation Assay for Protein Sequestration in
RNA-Mediated Disease
An RNA-mediated pathogenic mechanism has been proposed
for additional microsatellite diseases with different non-coding
expansion motifs, including FXTAS, SCA10, SCA12, Huntington
disease-like 2 (HDL2), and C9orf72 ALS/FTS (Echeverria and1166 Cell Reports 12, 1159–1168, August 18, 2015 ª2015 The AuthoCooper, 2012; Goodwin and Swanson, 2014). For C9 ALS/
FTD, multiple GGGGCCexp-binding proteins have been identi-
fied, including ADARB2, HNRNPA2B1, HNRNPA3, HNRNPH1,
NCL, PURA, and SRSF1 (Lee et al., 2013b; Mori et al.,
2013a; Reddy et al., 2013). Unfortunately, it is not clear whether
any of these factors are effectively sequestered by the corre-
sponding expansion RNAs in human tissues. Here, we demon-
strate that HITS-CLIP provides an in situ validation technique
for proteins that crosslink directly to tandem repeat expansions
in frozen autopsy tissue. Although some protein-RNAexp inter-
actions may be less susceptible to UV-light-induced crosslink-
ing and indirect binding events would not be captured by
HITS-CLIP, this in situ method provides an important tool that
complements studies based on RNA-binding characteristics
in vitro and co-localization with RNA foci in cells and tissues.
Since the development of genetic models is both time con-
suming and costly, we recommend HITS-CLIP be performed
prior to embarking on full-scale animal projects designed to
investigate the role of candidate sequestered factors in micro-
satellite expansion disease.
EXPERIMENTAL PROCEDURES
Human Tissues and Genotyping
Autopsy tissues were obtained from brain (frontal cortex and hippocampus) of
DM1, DM2, and control patients (Table S5). Protocols were approved by the
institutional ethics committee and the University of Minnesota and University
of Florida human subjects review boards, and all patients provided written
informed consent. Genotyping for repeat expansions was performed using
either genomic blot analysis or PCR.
MouseMbnl Compound-Knockout Generation and Characterization
Constitutive and conditional Mbnl2 (Mbnl2 DE2/DE2, Mbnl2c/c) and con-
stitutive Mbnl1 (Mbnl1 DE3/DE3) KO mice have been described (Charizanis
et al., 2012; Kanadia et al., 2003). Transgenic Nestin-Cre mice (B6.Cg-
Tg(Nes-cre)1Kln/J Strain 003771, JAX) were used to generate Nestin-
Cre DKOs (Mbnl1DE3/DE3, Mbnl2c/c; Nestin-Cre+/) and controls
(Mbnl1+/+; Mbnl2+/+; Nestin-Cre/, Mbnl1+/+; Mbnl2+/+; Nestin-Cre+/,
Mbnl1DE3/DE3; Mbnl2+/+; Nestin-Cre/, Mbnl1DE3/DE3; Mbnl2+/+; Nestin-
Cre+/, Mbnl1+/+, Mbnl2c/c; Nestin-Cre/; Mbnl1+/+, Mbnl2c/c; Nestin-
Cre+/ and Mbnl1DE3/DE3, Mbnl2c/c; Nestin-Cre/). Motor function
(accelerating rotarod) and grip strength were assessed as described pre-
viously (Lee et al., 2013a). All animal procedures were approved by the
University of Florida institutional animal care and use committee.
HITS-CLIP and dCLIP
HITS-CLIP was performed as described previously (Charizanis et al., 2012;
Jensen and Darnell, 2008), with the following modifications. Autopsy-derived
frozen brain tissues (hippocampus and frontal cortex) from control, disease
control (ALS), DM1, and DM2 (25 mg frozen tissue, n = 3 each) were pul-
verized in liquid nitrogen, UV crosslinked, and fragmented using RNase A
(553 mg/ml, high; 5.5 3 103 mg/mL, low). For immunoprecipitation, lysates
were treated at 90C for 10 min in 1% SDS, 5 mM EDTA, and 2.5 mM EGTA
(final concentration) followed by dilution to 0.1% SDS in PXL wash buffer
(Chi et al., 2009). Lysates were incubated on ice for 10 min, followed by addi-
tion of anti-MBNL2 monoclonal antibody (mAb) 3B4 (Santa Cruz sc-136167)
and immunoprecipitation at 4C for 2 hr. CLIP libraries were prepared using
linkers for Illumina sequencing, including a modified barcoded 50 linker (50-
AGGGAGGACGAUGCGNNNNG-30). Libraries were sequenced (36 cycles) us-
ing an Illumina Genome Analyzer IIx. The dCLIP analysis was performed as
described previously (Wang et al., 2014), with modifications for comparative
analysis of MBNL2 binding in control versus DM1 and DM2 brain (see Supple-
mental Experimental Procedures).rs
RNA-seq and Poly(A)-seq
For RNA-seq, 101-nt paired-end reads were generated from poly(A)-selected
DM1 and control frontal cortex RNA (n = 3 each). Reads were aligned to the
hg19 reference and a database of known exon junctions using OLego (Wu
et al., 2013) and processed using Quantas (Zhang et al., 2014) to identify differ-
entially spliced alternative exons. Exons with coverage R 20, jJj R 0.1 and
false discovery rate (FDR) % 0.05 were selected for analysis. Normalized
complexity maps were generated as described previously (Charizanis et al.,
2012) using RNA-seq, MBNL2 HITS-CLIP (Table S1), and genome-wide
(hg19) binding sites identified using mCarts (Zhang et al., 2013). Poly(A)-seq
libraries were prepared from frontal cortex tissue from WT, Nestin-Cre DKO,
human control, DM1, and DM2 frontal cortex (Table S5) as described else-
where (Derti et al., 2012), with several modifications (see Supplemental Exper-
imental Procedures for details).
Splicing and Polyadenylation Validation Assays
To validate AS changes, RNAwas isolated from dissectedmouse and human
autopsy brain tissues (n = 3). RNA integrity values were obtained using the
Agilent 2100 Bioanalyzer (Table S5). RT-PCR splicing assays were performed
as previously described (Lee et al., 2013a) using gene-specific primers in
flanking exons (Table S6). Validation of APA changes was performed using
qRT-PCR (Batra et al., 2014) or a modified RT-PCR protocol, in which two
alternative pA sites were simultaneously amplified using gene-specific for-
ward primers and hybrid gene-specific/oligo(dT) reverse primers. Statisti-
cally significant AS and APA changes were identified using the unpaired
Student’s t test.
Two-Dimensional Gel Electrophoresis and Immunoblotting
Brain tissue was processed based on a previously published protocol (Fernan-
dez-Gomez et al., 2014). For isoelectrofocusing (IEF), strips (pH 3–11 non-
linear) were rehydrated with the protein homogenate overnight at room
temperature and IEF performed with an IPGphor III Isoelectrofocusing unit
(GE Heathcare) at 20C (see Supplemental Experimental Procedures for de-
tails). For phosphatase treatment, brain tissue was added to 10 volumes of
10 mM Tris and 320 mM sucrose supplemented with a cocktail of protease in-
hibitors (Roche Complete Mini EDTA-free) and 30 nM of okadaic acid (Calbio-
chem) and homogenized followed by sonication. Dephosphorylation was per-
formedwith 50 mg of protein in a final volume of 30 ml of Tris-sucrose buffer with
4 ml of 50 mM HEPES (pH 7.5), 10 mM NaCl, 2mM DTT, 0.01% Brj35 3 buffer
(New England Biolabs), 4 ml of a 10 mMMnCl2 solution, and 2 ml lambda phos-
phatase (New England Biolabs). The mixture was mixed and incubated for 3 hr
at 30C, and the reaction was stopped by heating the homogenate and addi-
tion of lysis buffer.
ACCESSION NUMBERS
Sequencing data from HITS-CLIP and poly(A)-seq were deposited to the NCBI
GEO and are available under accession number GEO: GSE68890.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.07.029.
AUTHOR CONTRIBUTIONS
M.G., A.M., N.S., andM.S.S. designed the study and prepared themanuscript;
M.G. and R.B. performed HITS-CLIP and poly(A)-seq; M.G., R.B., and K.C.
contributed the computational analysis; M.G., A.M., K.Y.L., and R.B. per-
formed AS and APA assays; S.M.W.-V. and C.Z. performed the human
RNA-seq analysis; K.Y.L. produced and characterized the control and Nes-
tin-Cre mice; F.J.F.G., L.B., and N.S. analyzed tau isoform expression; S.E.
developed the dephosphorylation assay; T.R., L.P.W.R., T.K., and A.M. deter-
mined DMPK CTG and CNBP CCTG expansion lengths; and T.K., J.D., K.T.,
and J.W.D. contributed human control and disease samples.CellACKNOWLEDGMENTS
We thank J. Lewis for discussions on tauopathies, UF Research Computing for
computational resources, and J. Cleary and E. Wang for comments on the
manuscript. This study was supported by grants from the NIH (AR046799
and NS058901, to M.S.S.), INSERM (to L.B. and N.S.), CNRS (to L.B.), France
Alzheimer and AFM (to N.S.), DN2M and ANR NeuroSplice (to L.B., N.S.,
F.J.F.G., and S.E.), LabEx and DISTALZ (to L.B., N.S., and S.E.), and the Uni-
versity of Lille, CHR of Lille and Region Nord Pas-de Calais (to N.S.).
Received: March 24, 2015
Revised: June 24, 2015
Accepted: July 14, 2015
Published: August 6, 2015
REFERENCES
Batra, R., Charizanis, K., Manchanda, M., Mohan, A., Li, M., Finn, D.J., Good-
win, M., Zhang, C., Sobczak, K., Thornton, C.A., and Swanson, M.S. (2014).
Loss of MBNL leads to disruption of developmentally regulated alternative pol-
yadenylation in RNA-mediated disease. Mol. Cell 56, 311–322.
Carpentier, C., Ghanem, D., Fernandez-Gomez, F.J., Jumeau, F., Philippe,
J.V., Freyermuth, F., Labudeck, A., Eddarkaoui, S., Dhaenens, C.M., Holt, I.,
et al. (2014). Tau exon 2 responsive elements deregulated in myotonic dystro-
phy type I are proximal to exon 2 and synergistically regulated by MBNL1 and
MBNL2. Biochim. Biophys. Acta 1842, 654–664.
Charizanis, K., Lee, K.Y., Batra, R., Goodwin, M., Zhang, C., Yuan, Y., Shiue,
L., Cline, M., Scotti, M.M., Xia, G., et al. (2012). Muscleblind-like 2-mediated
alternative splicing in the developing brain and dysregulation in myotonic dys-
trophy. Neuron 75, 437–450.
Chi, S.W., Zang, J.B., Mele, A., and Darnell, R.B. (2009). Argonaute HITS-CLIP
decodes microRNA-mRNA interaction maps. Nature 460, 479–486.
Cleary, J.D., and Ranum, L.P. (2014). Repeat associated non-ATG (RAN)
translation: new starts in microsatellite expansion disorders. Curr. Opin.
Genet. Dev. 26, 6–15.
Derti, A., Garrett-Engele, P., Macisaac, K.D., Stevens, R.C., Sriram, S., Chen,
R., Rohl, C.A., Johnson, J.M., and Babak, T. (2012). A quantitative atlas of pol-
yadenylation in five mammals. Genome Res. 22, 1173–1183.
Dhaenens, C.M., Schraen-Maschke, S., Tran, H., Vingtdeux, V., Ghanem, D.,
Leroy, O., Delplanque, J., Vanbrussel, E., Delacourte, A., Vermersch, P., et al.
(2008). Overexpression of MBNL1 fetal isoforms and modified splicing of Tau
in the DM1 brain: two individual consequences of CUG trinucleotide repeats.
Exp. Neurol. 210, 467–478.
Echeverria, G.V., and Cooper, T.A. (2012). RNA-binding proteins in micro-
satellite expansion disorders: mediators of RNA toxicity. Brain Res. 1462,
100–111.
Fardaei, M., Rogers, M.T., Thorpe, H.M., Larkin, K., Hamshere, M.G., Harper,
P.S., and Brook, J.D. (2002). Three proteins, MBNL, MBLL and MBXL, co-
localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and
DM2 cells. Hum. Mol. Genet. 11, 805–814.
Fernandez-Gomez, F.J., Jumeau, F., Derisbourg,M., Burnouf, S., Tran, H., Ed-
darkaoui, S., Obriot, H., Dutoit-Lefevre, V., Deramecourt, V., Mitchell, V., et al.
(2014). Consensus brain-derived protein, extraction protocol for the study of
human andmurine brain proteome using both 2D-DIGE andmini 2DE immuno-
blotting. J. Vis. Exp. 86, e51339.
Gemayel, R., Vinces, M.D., Legendre, M., and Verstrepen, K.J. (2010). Variable
tandem repeats accelerate evolution of coding and regulatory sequences.
Annu. Rev. Genet. 44, 445–477.
Goodwin,M., and Swanson, M.S. (2014). RNA-binding protein misregulation in
microsatellite expansion disorders. Adv. Exp. Med. Biol. 825, 353–388.
Ho, T.H., Charlet-B, N., Poulos, M.G., Singh, G., Swanson, M.S., and Cooper,
T.A. (2004). Muscleblind proteins regulate alternative splicing. EMBO J. 23,
3103–3112.Reports 12, 1159–1168, August 18, 2015 ª2015 The Authors 1167
Huin, V., Vasseur, F., Schraen-Maschke, S., Dhaenens, C.M., Devos, P., Du-
pont, K., Sergeant, N., Bue´e, L., Lacour, A., Hofmann-Radvanyi, H., and Sa-
blonnie`re, B. (2013). MBNL1 gene variants as modifiers of disease severity
in myotonic dystrophy type 1. J. Neurol. 260, 998–1003.
Jensen, K.B., and Darnell, R.B. (2008). CLIP: crosslinking and immunoprecip-
itation of in vivo RNA targets of RNA-binding proteins. Methods Mol. Biol. 488,
85–98.
Jiang, H., Mankodi, A., Swanson, M.S., Moxley, R.T., and Thornton, C.A.
(2004). Myotonic dystrophy type 1 is associated with nuclear foci of mutant
RNA, sequestration of muscleblind proteins and deregulated alternative
splicing in neurons. Hum. Mol. Genet. 13, 3079–3088.
Kanadia, R.N., Johnstone, K.A., Mankodi, A., Lungu, C., Thornton, C.A., Es-
son, D., Timmers, A.M., Hauswirth, W.W., and Swanson, M.S. (2003). A mu-
scleblind knockout model for myotonic dystrophy. Science 302, 1978–1980.
Kanadia, R.N., Shin, J., Yuan, Y., Beattie, S.G., Wheeler, T.M., Thornton, C.A.,
and Swanson, M.S. (2006). Reversal of RNA missplicing and myotonia after
muscleblind overexpression in amouse poly(CUG) model for myotonic dystro-
phy. Proc. Natl. Acad. Sci. USA 103, 11748–11753.
Kim, D.H., Langlois, M.A., Lee, K.B., Riggs, A.D., Puymirat, J., and Rossi, J.J.
(2005). HnRNP H inhibits nuclear export of mRNA containing expanded CUG
repeats and a distal branch point sequence. Nucleic Acids Res. 33, 3866–
3874.
Kino, Y., Washizu, C., Kurosawa, M., Oma, Y., Hattori, N., Ishiura, S., and Nu-
kina, N. (2015). Nuclear localization of MBNL1: splicing-mediated autoregula-
tion and repression of repeat-derived aberrant proteins. Hum. Mol. Genet. 24,
740–756.
Kwon, I., Xiang, S., Kato, M., Wu, L., Theodoropoulos, P., Wang, T., Kim, J.,
Yun, J., Xie, Y., and McKnight, S.L. (2014). Poly-dipeptides encoded by the
C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science
345, 1139–1145.
Laurent, F.X., Sureau, A., Klein, A.F., Trouslard, F., Gasnier, E., Furling, D., and
Marie, J. (2012). New function for the RNA helicase p68/DDX5 as a modifier of
MBNL1 activity on expandedCUG repeats. Nucleic Acids Res. 40, 3159–3171.
Lee, K.Y., Li, M., Manchanda, M., Batra, R., Charizanis, K., Mohan, A., Warren,
S.A., Chamberlain, C.M., Finn, D., Hong, H., et al. (2013a). Compound loss of
muscleblind-like function in myotonic dystrophy. EMBO Mol. Med. 5, 1887–
1900.
Lee, Y.B., Chen, H.J., Peres, J.N., Gomez-Deza, J., Attig, J., Stalekar, M.,
Troakes, C., Nishimura, A.L., Scotter, E.L., Vance, C., et al. (2013b). Hexanu-
cleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA
binding proteins, and are neurotoxic. Cell Rep. 5, 1178–1186.
Liu, C., and Go¨tz, J. (2013). Profiling murine tau with 0N, 1N and 2N isoform-
specific antibodies in brain and peripheral organs reveals distinct subcellular
localization, with the 1N isoform being enriched in the nucleus. PLoS ONE 8,
e84849.
Miller, J.W., Urbinati, C.R., Teng-Umnuay, P., Stenberg, M.G., Byrne, B.J.,
Thornton, C.A., and Swanson, M.S. (2000). Recruitment of humanmuscleblind
proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO
J. 19, 4439–4448.
Mizielinska, S., Gro¨nke, S., Niccoli, T., Ridler, C.E., Clayton, E.L., Devoy, A.,
Moens, T., Norona, F.E., Woollacott, I.O., Pietrzyk, J., et al. (2014). C9orf72
repeat expansions cause neurodegeneration in Drosophila through arginine-
rich proteins. Science 345, 1192–1194.
Mohan, A., Goodwin, M., and Swanson, M.S. (2014). RNA-protein interactions
in unstable microsatellite diseases. Brain Res. 1584, 3–14.
Mori, K., Lammich, S., Mackenzie, I.R., Forne´, I., Zilow, S., Kretzschmar, H.,
Edbauer, D., Janssens, J., Kleinberger, G., Cruts, M., et al. (2013a). hnRNP
A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-
negative inclusions in the hippocampus of patients with C9orf72 mutations.
Acta Neuropathol. 125, 413–423.
Mori, K., Weng, S.M., Arzberger, T., May, S., Rentzsch, K., Kremmer, E.,
Schmid, B., Kretzschmar, H.A., Cruts, M., Van Broeckhoven, C., et al.1168 Cell Reports 12, 1159–1168, August 18, 2015 ª2015 The Autho(2013b). The C9orf72 GGGGCC repeat is translated into aggregating dipep-
tide-repeat proteins in FTLD/ALS. Science 339, 1335–1338.
Nelson, D.L., Orr, H.T., and Warren, S.T. (2013). The unstable repeats–three
evolving faces of neurological disease. Neuron 77, 825–843.
Niblock, M., and Gallo, J.M. (2012). Tau alternative splicing in familial and spo-
radic tauopathies. Biochem. Soc. Trans. 40, 677–680.
Pettersson, O.J., Aagaard, L., Andrejeva, D., Thomsen, R., Jensen, T.G., and
Damgaard, C.K. (2014). DDX6 regulates sequestered nuclear CUG-expanded
DMPK-mRNA in dystrophia myotonica type 1. Nucleic Acids Res. 42, 7186–
7200.
Poulos, M.G., Batra, R., Li, M., Yuan, Y., Zhang, C., Darnell, R.B., and Swan-
son, M.S. (2013). Progressive impairment of muscle regeneration in muscle-
blind-like 3 isoform knockout mice. Hum. Mol. Genet. 22, 3547–3558.
Rau, F., Freyermuth, F., Fugier, C., Villemin, J.P., Fischer, M.C., Jost, B., Dem-
bele, D., Gourdon, G., Nicole, A., Duboc, D., et al. (2011). Misregulation of miR-
1 processing is associated with heart defects in myotonic dystrophy. Nat.
Struct. Mol. Biol. 18, 840–845.
Ravel-Chapuis, A., Be´langer, G., Yadava, R.S., Mahadevan, M.S., DesGroseil-
lers, L., Co^te´, J., and Jasmin, B.J. (2012). The RNA-binding protein Staufen1 is
increased in DM1 skeletal muscle and promotes alternative pre-mRNA
splicing. J. Cell Biol. 196, 699–712.
Reddy, K., Zamiri, B., Stanley, S.Y., Macgregor, R.B., Jr., and Pearson, C.E.
(2013). The disease-associated r(GGGGCC)n repeat from the C9orf72 gene
forms tract length-dependent uni- and multimolecular RNA G-quadruplex
structures. J. Biol. Chem. 288, 9860–9866.
Sergeant, N., Sablonnie`re, B., Schraen-Maschke, S., Ghestem, A., Maurage,
C.A., Wattez, A., Vermersch, P., and Delacourte, A. (2001). Dysregulation of
human brain microtubule-associated tau mRNA maturation in myotonic dys-
trophy type 1. Hum. Mol. Genet. 10, 2143–2155.
Suenaga, K., Lee, K.Y., Nakamori, M., Tatsumi, Y., Takahashi, M.P., Fujimura,
H., Jinnai, K., Yoshikawa, H., Du, H., Ares, M., Jr., et al. (2012). Muscleblind-
like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy
brain. PLoS ONE 7, e33218.
Wang, E.T., Cody, N.A., Jog, S., Biancolella, M., Wang, T.T., Treacy, D.J., Luo,
S., Schroth, G.P., Housman, D.E., Reddy, S., et al. (2012). Transcriptome-wide
regulation of pre-mRNA splicing and mRNA localization by muscleblind pro-
teins. Cell 150, 710–724.
Wang, T., Xie, Y., and Xiao, G. (2014). dCLIP: a computational approach for
comparative CLIP-seq analyses. Genome Biol. 15, R11.
Wen, X., Tan, W., Westergard, T., Krishnamurthy, K., Markandaiah, S.S., Shi,
Y., Lin, S., Shneider, N.A., Monaghan, J., Pandey, U.B., et al. (2014). Antisense
proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nu-
clear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84,
1213–1225.
Wu, J., Anczuko´w, O., Krainer, A.R., Zhang, M.Q., and Zhang, C. (2013).
OLego: fast and sensitive mapping of spliced mRNA-Seq reads using small
seeds. Nucleic Acids Res. 41, 5149–5163.
Zhang, C., Lee, K.Y., Swanson, M.S., and Darnell, R.B. (2013). Prediction of
clustered RNA-binding protein motif sites in the mammalian genome. Nucleic
Acids Res. 41, 6793–6807.
Zhang, Y., Chen, K., Sloan, S.A., Bennett, M.L., Scholze, A.R., O’Keeffe, S.,
Phatnani, H.P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014). An
RNA-sequencing transcriptome and splicing database of glia, neurons, and
vascular cells of the cerebral cortex. J. Neurosci. 34, 11929–11947.
Zu, T., Gibbens, B., Doty, N.S., Gomes-Pereira, M., Huguet, A., Stone, M.D.,
Margolis, J., Peterson, M., Markowski, T.W., Ingram, M.A., et al. (2011).
Non-ATG-initiated translation directed by microsatellite expansions. Proc.
Natl. Acad. Sci. USA 108, 260–265.
Zu, T., Liu, Y., Ban˜ez-Coronel, M., Reid, T., Pletnikova, O., Lewis, J., Miller,
T.M., Harms, M.B., Falchook, A.E., Subramony, S.H., et al. (2013). RAN pro-
teins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotem-
poral dementia. Proc. Natl. Acad. Sci. USA 110, E4968–E4977.rs
